Skip to main content
EQ
NASDAQ Life Sciences

Equillium Secures Funding into 2029, Reports Q4 2025 Financials and Advances EQ504 to Phase 1

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$2.06
Mkt Cap
$125.44M
52W Low
$0.27
52W High
$2.7
52W Position info
663% above low
Off High info
24% below high
Rel. Volume info
0.3× avg
Market data snapshot near publication time

EQ has more than doubled off its 52-week low of $0.27 on light trading volume (0.3× avg).

Summary

Equillium announced its Q4 and full-year 2025 financial results, highlighting a strengthened cash position from recent financings that is projected to fund operations into 2029, and plans to initiate a Phase 1 study for EQ504.


Key Events · Financing and Capital Events · EQ

  • Extended Cash Runway

    Cash and equivalents, including a recently completed $35 million financing, are expected to fund operations into 2029.

  • Q4 and Full Year 2025 Financials

    Reported a Q4 2025 net loss of $(0.04) per share and a full-year net loss of $(0.39) per share.

  • EQ504 Clinical Advancement

    Completed preclinical work and plans to initiate a Phase 1 proof-of-mechanism study in mid-2026, with data expected approximately six months thereafter.

  • Recent Financings Confirmed

    Confirmed the completion of a $35 million private placement in March 2026, following an 'up to $50 million' financing in August 2025.


Analysis · EQ · Life Sciences

This 8-K provides a critical update on Equillium's financial stability, confirming that recent financings, including a $35 million private placement in March 2026, have extended the company's cash runway into 2029. For a clinical-stage biotechnology company, securing long-term funding significantly de-risks its operations and provides the necessary capital to advance its pipeline, specifically the planned Phase 1 study for EQ504. While the company reported a net loss for Q4 and full-year 2025, the extended financial runway is a strong positive signal for investors, indicating reduced near-term liquidity concerns and a clear path for clinical development.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 48.3% of the 1982 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, EQ was trading at $2.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $125.4M. The 52-week trading range was $0.27 to $2.70. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

EQ - Latest Insights

EQ
Nov 12, 2026, 4:20 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $1.34
Real-time Price: $1.37 info
Change: +$0.030 (+2%) info
Market Cap: $106.199M info
EQ
Oct 26, 2026, 5:09 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.29
Real-time Price: $1.37 info
Change: +$0.080 (+6%) info
Market Cap: $106.199M info
EQ
Oct 26, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.12
Real-time Price: $1.37 info
Change: +$0.2497 (+22%) info
Market Cap: $106.199M info
EQ
Oct 05, 2026, 5:06 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.42
Real-time Price: $1.37 info
Change: -$0.050 (-4%) info
Market Cap: $106.199M info
EQ
Oct 05, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.51
Real-time Price: $1.37 info
Change: -$0.140 (-9%) info
Market Cap: $106.199M info